Breakthrough against stomach cancer: new drug extended lifespan

A new biotechnological approach has shown successful results in treating severe and fast-spreading forms of stomach cancer. According to clinical trials conducted in China, the satri-cel drug developed on the basis of CAR-T technology helped increase patients’ lifespan by an average of 40%.

CAR-T is a method in which the patient's own immune cells are reprogrammed to gain the ability to destroy cancer cells. This time, the method was tested on 156 patients with stomach and gastroesophageal cancer who had previously undergone two unsuccessful treatment courses.

The study results were published in the journal "The Lancet." It was noted that patients who received satri-cel lived an average of 7.9 months, while in the traditional therapy group it was 5.5 months. Furthermore, tumors shrank significantly in 22% of patients (compared to 4% with conventional treatment).

The effect of satri-cel is achieved by blocking the protein CLDN18.2, which contributes to tumor growth. The drug reactivates the immune system and restores the body’s ability to fight cancer.

Despite its effectiveness, the therapy is not perfect. Almost all patients experienced side effects such as a decrease in blood cell count. However, experts believe these effects can be managed.

Researchers emphasize that this is not a final cure for the disease but an important step in the fight against one of the most aggressive forms of cancer, offering patients extended and higher quality life.

Zamin.uz continues to monitor scientific breakthroughs and promptly inform its readers about key developments in the global fight against cancer.